{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T13:29:50Z","timestamp":1790688590481,"version":"4.1.0"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T00:00:00Z","timestamp":1779926400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T00:00:00Z","timestamp":1785456000000},"content-version":"vor","delay-in-days":64,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006606","name":"Natural Science Foundation of Tianjin Municipality","doi-asserted-by":"publisher","award":["22JCYBJC01230"],"award-info":[{"award-number":["22JCYBJC01230"]}],"id":[{"id":"10.13039\/501100006606","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hereditas"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) poses a considerable challenge for the long-term treatment of non-small cell lung cancer (NSCLC). This study aims to identify a novel biomarker associated with osimertinib resistance and explore its role in EGFR-TKI resistance in lung adenocarcinoma (LUAD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Comprehensive bioinformatics analysis were done using transcriptomic data from the TCGA and GEO databases to identify genes associated with osimertinib tolerance. Candidate genes were further screened against a histone modification-related gene set from MSigDB, leading to the identification of TLE1. The hub gene, TLE1, was further evaluated through survival analysis, GSEA and CIBERSORT analyses. Loss-of-function experiments performed\n                      <jats:italic>in vitro<\/jats:italic>\n                      were utilized to assess the impact of TLE1 on osimertinib resistance in LUAD.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>TLE1 was of particularly noteworthy, exhibiting elevated expression in LUAD, especially in stage IV patients, and was associated with poor prognosis. GSEA results showed that mTOR, VEGF and HIF-1 signaling pathways were notably activated in the high TLE1 expression group. CIBERSORT analysis markedly elevated levels of regulatory T cells (Tregs) in the TLE1 high expression group. Additionally, epithelial-mesenchymal transition (EMT) scores were significantly elevated in osimertinib tolerant groups and exhibited a positive correlation with TLE1 expression. Furthermore, TLE1 expression was significantly higher in osimertinib-resistant PC9 cells compared to parental PC9 cells. Downregulation of TLE1 enhanced the sensitivity of osimertinib-resistant PC9 cells to osimertinib.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>TLE1 was identified as a critical gene associated with osimertinib tolerance, influencing LUAD progression, potentially serving as a novel therapeutic target.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical trial number<\/jats:title>\n                    <jats:p>Not applicable.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s41065-026-00690-x","type":"journal-article","created":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T13:54:29Z","timestamp":1779976469000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["TLE1 as a key regulator of osimertinib resistance and EMT in lung adenocarcinoma: implications for prognosis and immunotherapy response"],"prefix":"10.1186","volume":"163","author":[{"given":"Na","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianlin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruixia","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiduan","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenglu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,28]]},"reference":[{"issue":"1","key":"690_CR1","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.ccm.2017.10.003","volume":"39","author":"T Inage","year":"2018","unstructured":"Inage T, Nakajima T, Yoshino I, Yasufuku K. Early lung cancer detection. Clin Chest Med. 2018;39(1):45\u201355. https:\/\/doi.org\/10.1016\/j.ccm.2017.10.003.","journal-title":"Clin Chest Med"},{"issue":"4","key":"690_CR2","doi-asserted-by":"publisher","first-page":"383","DOI":"10.3892\/etm.2024.12672","volume":"28","author":"Q Zhang","year":"2024","unstructured":"Zhang Q, Zhang M. Recent advances in lung cancer organoid (tumoroid) research (Review). Exp Ther Med. 2024;28(4):383. https:\/\/doi.org\/10.3892\/etm.2024.12672.","journal-title":"Exp Ther Med"},{"issue":"7","key":"690_CR3","doi-asserted-by":"publisher","first-page":"4382","DOI":"10.1007\/s12010-023-04595-7","volume":"196","author":"R Kaur","year":"2024","unstructured":"Kaur R, Suresh PK. Chemoresistance mechanisms in non-small cell lung cancer-opportunities for drug repurposing. Appl Biochem Biotechnol. 2024;196(7):4382\u2013438. https:\/\/doi.org\/10.1007\/s12010-023-04595-7.","journal-title":"Appl Biochem Biotechnol"},{"issue":"1","key":"690_CR4","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s12957-024-03303-x","volume":"22","author":"R Li","year":"2024","unstructured":"Li R, Qiu J, Li Z, Li H, Tang Z, Yu W, et al. Prognostic significance and survival benefits of postoperative adjuvant chemotherapy in patients with stage IA lung adenocarcinoma with non-predominant micropapillary components. World J Surg Oncol. 2024;22(1):32. https:\/\/doi.org\/10.1186\/s12957-024-03303-x.","journal-title":"World J Surg Oncol"},{"issue":"4","key":"690_CR5","doi-asserted-by":"publisher","first-page":"e181","DOI":"10.1002\/mco2.181","volume":"3","author":"GH Liu","year":"2020","unstructured":"Liu GH, Chen T, Zhang X, Ma XL, Shi HS. Small molecule inhibitors targeting the cancers. MedComm (2020). 2022;3(4):e181. https:\/\/doi.org\/10.1002\/mco2.181.","journal-title":"MedComm (2020)"},{"issue":"4","key":"690_CR6","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1002\/mco2.105","volume":"2","author":"Y Cheng","year":"2021","unstructured":"Cheng Y, Zhang T, Xu Q. Therapeutic advances in non-small cell lung cancer: Focus on clinical development of targeted therapy and immunotherapy. MedComm (2020). 2021;2(4):692\u2013729. . https:\/\/doi.org\/10.1002\/mco2.105.","journal-title":"MedComm (2020)"},{"issue":"25","key":"690_CR7","doi-asserted-by":"publisher","first-page":"2380","DOI":"10.1056\/NEJMoa0909530","volume":"362","author":"M Maemondo","year":"2010","unstructured":"Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010;362(25):2380\u20138. https:\/\/doi.org\/10.1056\/NEJMoa0909530.","journal-title":"N Engl J Med"},{"issue":"2","key":"690_CR8","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S1470-2045(09)70364-X","volume":"11","author":"T Mitsudomi","year":"2010","unstructured":"Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 2010;11(2):121\u20138. https:\/\/doi.org\/10.1016\/S1470-2045(09)70364-X.","journal-title":"Lancet Oncol"},{"issue":"1","key":"690_CR9","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1056\/NEJMoa1913662","volume":"382","author":"SS Ramalingam","year":"2020","unstructured":"Ramalingam SS, Vansteenkiste J, Planchard D, Cho BC, Gray JE, Ohe Y, et al. Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC. N Engl J Med. 2020;382(1):41\u201350. https:\/\/doi.org\/10.1056\/NEJMoa1913662.","journal-title":"N Engl J Med"},{"issue":"9","key":"690_CR10","doi-asserted-by":"publisher","first-page":"e447","DOI":"10.1016\/S1470-2045(15)00246-6","volume":"16","author":"CS Tan","year":"2015","unstructured":"Tan CS, Gilligan D, Pacey S. Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer. Lancet Oncol. 2015;16(9):e447\u201359. https:\/\/doi.org\/10.1016\/S1470-2045(15)00246-6.","journal-title":"Lancet Oncol"},{"issue":"suppl1","key":"690_CR11","doi-asserted-by":"publisher","first-page":"i10","DOI":"10.1093\/annonc\/mdx703","volume":"29","author":"D Westover","year":"2018","unstructured":"Westover D, Zugazagoitia J, Cho BC, Lovly CM, Paz-Ares L. Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors. Ann Oncol. 2018;29(suppl1):i10\u20139. https:\/\/doi.org\/10.1093\/annonc\/mdx703.","journal-title":"Ann Oncol"},{"issue":"18","key":"690_CR12","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1056\/NEJMoa1411817","volume":"372","author":"PA Janne","year":"2015","unstructured":"Janne PA, Yang JC, Kim DW, Planchard D, Ohe Y, Ramalingam SS, et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med. 2015;372(18):1689\u201399. https:\/\/doi.org\/10.1056\/NEJMoa1411817.","journal-title":"N Engl J Med"},{"issue":"2","key":"690_CR13","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1056\/NEJMoa1713137","volume":"378","author":"JC Soria","year":"2018","unstructured":"Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, et al. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. N Engl J Med. 2018;378(2):113\u201325. https:\/\/doi.org\/10.1056\/NEJMoa1713137.","journal-title":"N Engl J Med"},{"issue":"6","key":"690_CR14","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1039\/d1cb00115a","volume":"2","author":"L Hu","year":"2021","unstructured":"Hu L, Tao Z, Wu X. Insights into auto-S-fatty acylation: targets, druggability, and inhibitors. RSC Chem Biol. 2021;2(6):1567\u201379. https:\/\/doi.org\/10.1039\/d1cb00115a.","journal-title":"RSC Chem Biol"},{"issue":"8","key":"690_CR15","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1016\/j.ccell.2023.07.005","volume":"41","author":"FJ de Miguel","year":"2023","unstructured":"de Miguel FJ, Gentile C, Feng WW, Silva SJ, Sankar A, Exposito F, et al. Mammalian SWI\/SNF chromatin remodeling complexes promote tyrosine kinase inhibitor resistance in EGFR-mutant lung cancer. Cancer Cell. 2023;41(8):1516\u2013e349. https:\/\/doi.org\/10.1016\/j.ccell.2023.07.005.","journal-title":"Cancer Cell"},{"issue":"1","key":"690_CR16","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/s41392-024-01778-4","volume":"9","author":"J Zhang","year":"2024","unstructured":"Zhang J, Zhao K, Zhou W, Kang R, Wei S, Shu Y, et al. Tet methylcytosine dioxygenase 2 (TET2) deficiency elicits EGFR-TKI (tyrosine kinase inhibitors) resistance in non-small cell lung cancer. Signal Transduct Target therapy. 2024;9(1):65. https:\/\/doi.org\/10.1038\/s41392-024-01778-4.","journal-title":"Signal Transduct Target therapy"},{"issue":"9","key":"690_CR17","doi-asserted-by":"publisher","first-page":"15971","DOI":"10.18632\/oncotarget.13278","volume":"8","author":"D Yuan","year":"2017","unstructured":"Yuan D, Yang X, Yuan Z, Zhao Y, Guo J. TLE1 function and therapeutic potential in cancer. Oncotarget. 2017;8(9):15971\u20136. https:\/\/doi.org\/10.18632\/oncotarget.13278.","journal-title":"Oncotarget"},{"issue":"3","key":"690_CR18","doi-asserted-by":"publisher","first-page":"36","DOI":"10.3892\/br.2024.1914","volume":"22","author":"X Yao","year":"2025","unstructured":"Yao X, Roberts N, Iheukwumere P, Carmouche A, Chen R, Dela Cruz MC, et al. TLE1 corepressor promotes gefitinib resistance in lung cancer A549 cells via E\u2013cadherin silencing. Biomed Rep. 2025;22(3):36. https:\/\/doi.org\/10.3892\/br.2024.1914.","journal-title":"Biomed Rep"},{"issue":"3\u20134","key":"690_CR19","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.bbrc.2014.11.007","volume":"455","author":"X Yao","year":"2014","unstructured":"Yao X, Ireland SK, Pham T, Temple B, Chen R, Raj MH, et al. TLE1 promotes EMT in A549 lung cancer cells through suppression of E-cadherin. Biochem Biophys Res Commun. 2014;455(3\u20134):277\u201384. https:\/\/doi.org\/10.1016\/j.bbrc.2014.11.007.","journal-title":"Biochem Biophys Res Commun"},{"issue":"3","key":"690_CR20","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1158\/0008-5472.CAN-05-1634","volume":"66","author":"T Allen","year":"2006","unstructured":"Allen T, van Tuyl M, Iyengar P, Jothy S, Post M, Tsao MS, et al. Grg1 acts as a lung-specific oncogene in a transgenic mouse model. Cancer Res. 2006;66(3):1294\u2013301. https:\/\/doi.org\/10.1158\/0008-5472.CAN-05-1634.","journal-title":"Cancer Res"},{"issue":"7","key":"690_CR21","doi-asserted-by":"publisher","first-page":"3251","DOI":"10.21037\/tlcr-21-582","volume":"10","author":"Q Ma","year":"2021","unstructured":"Ma Q, Xiao F, Hao Y, Song Z, Zhang J, Si C, et al. The prognostic role of the Transducin-like Enhancer of split protein family in lung adenocarcinoma. Transl Lung Cancer Res. 2021;10(7):3251\u201363. https:\/\/doi.org\/10.21037\/tlcr-21-582.","journal-title":"Transl Lung Cancer Res"},{"issue":"5","key":"690_CR22","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1089\/omi.2011.0118","volume":"16","author":"G Yu","year":"2012","unstructured":"Yu G, Wang LG, Han Y, He QY. clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. 2012;16(5):284\u20137. https:\/\/doi.org\/10.1089\/omi.2011.0118.","journal-title":"OMICS"},{"key":"690_CR23","doi-asserted-by":"publisher","unstructured":"Wang Y, Liu C, Wan J, Sun X, Ma W, Ni H. Molecular cloning and characterization of a methyl parathion hydrolase from an organophosphorus-degrading bacterium, Serratia marcescens MEW06. FEMS Microbiol Lett. 2018;365(24). https:\/\/doi.org\/10.1093\/femsle\/fny279.","DOI":"10.1093\/femsle\/fny279"},{"issue":"11","key":"690_CR24","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.1101\/gr.1239303","volume":"13","author":"P Shannon","year":"2003","unstructured":"Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13(11):2498\u2013504. https:\/\/doi.org\/10.1101\/gr.1239303.","journal-title":"Genome Res"},{"issue":"3","key":"690_CR25","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1002\/dvdy.24485","volume":"247","author":"DL Gibbons","year":"2018","unstructured":"Gibbons DL, Creighton CJ. Pan-cancer survey of epithelial-mesenchymal transition markers across the Cancer Genome Atlas. Dev Dyn. 2018;247(3):555\u201364. https:\/\/doi.org\/10.1002\/dvdy.24485.","journal-title":"Dev Dyn"},{"issue":"5","key":"690_CR26","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nmeth.3337","volume":"12","author":"AM Newman","year":"2015","unstructured":"Newman AM, Liu CL, Green MR, Gentles AJ, Feng W, Xu Y, et al. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015;12(5):453\u20137. https:\/\/doi.org\/10.1038\/nmeth.3337.","journal-title":"Nat Methods"},{"key":"690_CR27","doi-asserted-by":"publisher","unstructured":"Maeser D, Gruener RF, Huang RS. oncoPredict: an R package for predicting in vivo or cancer patient drug response and biomarkers from cell line screening data. Brief Bioinform. 2021;22(6). https:\/\/doi.org\/10.1093\/bib\/bbab260.","DOI":"10.1093\/bib\/bbab260"},{"issue":"1","key":"690_CR28","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1186\/gb-2008-9-1-205","volume":"9","author":"BH Jennings","year":"2008","unstructured":"Jennings BH, Ish-Horowicz D. The Groucho\/TLE\/Grg family of transcriptional co-repressors. Genome Biol. 2008;9(1):205. https:\/\/doi.org\/10.1186\/gb-2008-9-1-205.","journal-title":"Genome Biol"},{"issue":"4","key":"690_CR29","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1002\/jcb.20476","volume":"95","author":"M Gasperowicz","year":"2005","unstructured":"Gasperowicz M, Otto F. Mammalian Groucho homologs: redundancy or specificity? J Cell Biochem. 2005;95(4):670\u201387. https:\/\/doi.org\/10.1002\/jcb.20476.","journal-title":"J Cell Biochem"},{"issue":"1\u20132","key":"690_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/s0378-1119(00)00161-x","volume":"249","author":"G Chen","year":"2000","unstructured":"Chen G, Courey AJ. Groucho\/TLE family proteins and transcriptional repression. Gene. 2000;249(1\u20132):1\u201316. https:\/\/doi.org\/10.1016\/s0378-1119(00)00161-x.","journal-title":"Gene"},{"issue":"7","key":"690_CR31","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1002\/jor.21318","volume":"29","author":"SW Seo","year":"2011","unstructured":"Seo SW, Lee H, Lee HI, Kim HS. The role of TLE1 in synovial sarcoma. J Orthop Res. 2011;29(7):1131\u20136. https:\/\/doi.org\/10.1002\/jor.21318.","journal-title":"J Orthop Res"},{"issue":"11","key":"690_CR32","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1158\/1541-7786.MCR-12-0144","volume":"10","author":"C Brunquell","year":"2012","unstructured":"Brunquell C, Biliran H, Jennings S, Ireland SK, Chen R, Ruoslahti E. TLE1 is an anoikis regulator and is downregulated by Bit1 in breast cancer cells. Mol cancer research: MCR. 2012;10(11):1482\u201395. https:\/\/doi.org\/10.1158\/1541-7786.MCR-12-0144.","journal-title":"Mol cancer research: MCR"},{"issue":"10","key":"690_CR33","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1038\/nrclinonc.2017.44","volume":"14","author":"T Shibue","year":"2017","unstructured":"Shibue T, Weinberg RA. EMT, CSCs, and drug resistance: the mechanistic link and clinical implications. Nat Rev Clin Oncol. 2017;14(10):611\u201329. https:\/\/doi.org\/10.1038\/nrclinonc.2017.44.","journal-title":"Nat Rev Clin Oncol"},{"issue":"11","key":"690_CR34","doi-asserted-by":"publisher","first-page":"2990","DOI":"10.1158\/0008-5472.CAN-16-2300","volume":"77","author":"E Ichihara","year":"2017","unstructured":"Ichihara E, Westover D, Meador CB, Yan Y, Bauer JA, Lu P, et al. SFK\/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer. Cancer Res. 2017;77(11):2990\u20133000. https:\/\/doi.org\/10.1158\/0008-5472.CAN-16-2300.","journal-title":"Cancer Res"},{"issue":"9","key":"690_CR35","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1016\/j.ccell.2021.07.006","volume":"39","author":"K Tanaka","year":"2021","unstructured":"Tanaka K, Yu HA, Yang S, Han S, Selcuklu SD, Kim K, et al. Targeting Aurora B kinase prevents and overcomes resistance to EGFR inhibitors in lung cancer by enhancing BIM- and PUMA-mediated apoptosis. Cancer Cell. 2021;39(9):1245\u2013e616. https:\/\/doi.org\/10.1016\/j.ccell.2021.07.006.","journal-title":"Cancer Cell"},{"key":"690_CR36","doi-asserted-by":"publisher","first-page":"834731","DOI":"10.3389\/fgene.2022.834731","volume":"13","author":"S Xu","year":"2022","unstructured":"Xu S, Liu Y, Ma H, Fang S, Wei S, Li X, et al. A Novel Signature Integrated of Immunoglobulin, Glycosylation and Anti-Viral Genes to Predict Prognosis for Breast Cancer. Front Genet. 2022;13:834731. https:\/\/doi.org\/10.3389\/fgene.2022.834731.","journal-title":"Front Genet"},{"issue":"1","key":"690_CR37","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1186\/s12885-025-14246-1","volume":"25","author":"S Xu","year":"2025","unstructured":"Xu S, Chen Z, Chen X, Chu H, Huang X, Chen C, et al. Interplay of disulfidptosis and the tumor microenvironment across cancers: implications for prognosis and therapeutic responses. BMC Cancer. 2025;25(1):1113. https:\/\/doi.org\/10.1186\/s12885-025-14246-1.","journal-title":"BMC Cancer"},{"key":"690_CR38","doi-asserted-by":"publisher","first-page":"1325262","DOI":"10.1155\/sci\/1325262","volume":"2025","author":"P Wang","year":"2025","unstructured":"Wang P, Xu S, Guo Q, Zhao Y. Discovery of PAK2 as a Key Regulator of Cancer Stem Cell in Head and Neck Squamous Cell Carcinoma Using Multi-Omic Techniques. Stem cells Int. 2025;2025:1325262. https:\/\/doi.org\/10.1155\/sci\/1325262.","journal-title":"Stem cells Int"},{"issue":"3","key":"690_CR39","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1002\/cbin.12126","volume":"48","author":"X Zhou","year":"2024","unstructured":"Zhou X, Xia Q, Chen M, Zhang X, Huang M, Zheng X, et al. THBS1 promotes angiogenesis and accelerates ESCC malignant progression by the HIF-1\/VEGF signaling pathway. Cell Biol Int. 2024;48(3):311\u201324. https:\/\/doi.org\/10.1002\/cbin.12126.","journal-title":"Cell Biol Int"},{"key":"690_CR40","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.semcancer.2021.06.019","volume":"85","author":"L Yu","year":"2022","unstructured":"Yu L, Wei J, Liu P. Attacking the PI3K\/Akt\/mTOR signaling pathway for targeted therapeutic treatment in human cancer. Semin Cancer Biol. 2022;85:69\u201394. https:\/\/doi.org\/10.1016\/j.semcancer.2021.06.019.","journal-title":"Semin Cancer Biol"},{"key":"690_CR41","doi-asserted-by":"publisher","first-page":"110580","DOI":"10.1016\/j.intimp.2023.110580","volume":"122","author":"K Li","year":"2023","unstructured":"Li K, Quan L, Huang F, Li Y, Shen Z. ADAM12 promotes the resistance of lung adenocarcinoma cells to EGFR-TKI and regulates the immune microenvironment by activating PI3K\/Akt\/mTOR and RAS signaling pathways. Int Immunopharmacol. 2023;122:110580. https:\/\/doi.org\/10.1016\/j.intimp.2023.110580.","journal-title":"Int Immunopharmacol"},{"key":"690_CR42","doi-asserted-by":"publisher","first-page":"6633867","DOI":"10.1155\/2021\/6633867","volume":"2021","author":"Q Jin","year":"2021","unstructured":"Jin Q, Zheng J, Chen M, Jiang N, Xu X, Huang F. HIF-1 Inhibitor YC-1 Reverses the Acquired Resistance of EGFR-Mutant HCC827 Cell Line with MET Amplification to Gefitinib. Oxid Med Cell Longev. 2021;2021:6633867. https:\/\/doi.org\/10.1155\/2021\/6633867.","journal-title":"Oxid Med Cell Longev"},{"issue":"4","key":"690_CR43","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s12032-025-02652-1","volume":"42","author":"G Singh","year":"2025","unstructured":"Singh G, Rohit, Kumar, Aran KR. Targeting EGFR and PI3K\/mTOR pathways in glioblastoma: innovative therapeutic approaches. Med Oncol (Northwood Lond Engl). 2025;42(4):97. https:\/\/doi.org\/10.1007\/s12032-025-02652-1.","journal-title":"Med Oncol (Northwood Lond Engl)"},{"issue":"5","key":"690_CR44","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1111\/cas.14373","volume":"111","author":"KY Lee","year":"2020","unstructured":"Lee KY, Shueng PW, Chou CM, Lin BX, Lin MH, Kuo DY, et al. Elevation of CD109 promotes metastasis and drug resistance in lung cancer via activation of EGFR-AKT-mTOR signaling. Cancer Sci. 2020;111(5):1652\u201362. https:\/\/doi.org\/10.1111\/cas.14373.","journal-title":"Cancer Sci"},{"issue":"14","key":"690_CR45","doi-asserted-by":"publisher","first-page":"5820","DOI":"10.1158\/0008-5472.CAN-08-2819","volume":"69","author":"T Arumugam","year":"2009","unstructured":"Arumugam T, Ramachandran V, Fournier KF, Wang H, Marquis L, Abbruzzese JL, et al. Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer. Cancer Res. 2009;69(14):5820\u20138. https:\/\/doi.org\/10.1158\/0008-5472.CAN-08-2819.","journal-title":"Cancer Res"},{"issue":"3\u20134","key":"690_CR46","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s10555-009-9194-7","volume":"28","author":"DJ McConkey","year":"2009","unstructured":"McConkey DJ, Choi W, Marquis L, Martin F, Williams MB, Shah J, et al. Role of epithelial-to-mesenchymal transition (EMT) in drug sensitivity and metastasis in bladder cancer. Cancer Metastasis Rev. 2009;28(3\u20134):335\u201344. https:\/\/doi.org\/10.1007\/s10555-009-9194-7.","journal-title":"Cancer Metastasis Rev"},{"issue":"3","key":"690_CR47","doi-asserted-by":"publisher","first-page":"840","DOI":"10.3892\/ijo.2015.3084","volume":"47","author":"J Huang","year":"2015","unstructured":"Huang J, Li H, Ren G. Epithelial-mesenchymal transition and drug resistance in breast cancer (Review). Int J Oncol. 2015;47(3):840\u20138. https:\/\/doi.org\/10.3892\/ijo.2015.3084.","journal-title":"Int J Oncol"},{"issue":"2","key":"690_CR48","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1111\/cup.13596","volume":"47","author":"T Pukhalskaya","year":"2020","unstructured":"Pukhalskaya T, Smoller BR. TLE1 expression fails to distinguish between synovial sarcoma, atypical fibroxanthoma, and dermatofibrosarcoma protuberans. J Cutan Pathol. 2020;47(2):135\u20138. https:\/\/doi.org\/10.1111\/cup.13596.","journal-title":"J Cutan Pathol"},{"issue":"2","key":"690_CR49","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.yexmp.2015.08.009","volume":"99","author":"K Liu","year":"2015","unstructured":"Liu K, Sun B, Zhao X, Wang X, Li Y, Qiu Z, et al. Hypoxia induced epithelial-mesenchymal transition and vasculogenic mimicry formation by promoting Bcl-2\/Twist1 cooperation. Exp Mol Pathol. 2015;99(2):383\u201391. https:\/\/doi.org\/10.1016\/j.yexmp.2015.08.009.","journal-title":"Exp Mol Pathol"},{"key":"690_CR50","doi-asserted-by":"publisher","unstructured":"Li Q, Hong Y, Chen J, Zhou X, Tian X, Yu Y, et al. Hypoxia-Induced HIF-1alpha Expression Promotes Neurogenic Bladder Fibrosis via EMT and Pyroptosis. Cells. 2022;11(23). https:\/\/doi.org\/10.3390\/cells11233836.","DOI":"10.3390\/cells11233836"},{"issue":"1","key":"690_CR51","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s13020-022-00581-z","volume":"17","author":"R Yuan","year":"2022","unstructured":"Yuan R, Fan Q, Liang X, Han S, He J, Wang QQ, et al. Cucurbitacin B inhibits TGF-beta1-induced epithelial-mesenchymal transition (EMT) in NSCLC through regulating ROS and PI3K\/Akt\/mTOR pathways. Chin Med. 2022;17(1):24. https:\/\/doi.org\/10.1186\/s13020-022-00581-z.","journal-title":"Chin Med"},{"issue":"24","key":"690_CR52","doi-asserted-by":"publisher","first-page":"7291","DOI":"10.7150\/jca.46429","volume":"11","author":"L Chen","year":"2020","unstructured":"Chen L, Lin G, Chen K, Liang R, Wan F, Zhang C, et al. VEGF promotes migration and invasion by regulating EMT and MMPs in nasopharyngeal carcinoma. J Cancer. 2020;11(24):7291\u2013301. https:\/\/doi.org\/10.7150\/jca.46429.","journal-title":"J Cancer"},{"key":"690_CR53","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.biochi.2019.08.003","volume":"165","author":"M Karimi Roshan","year":"2019","unstructured":"Karimi Roshan M, Soltani A, Soleimani A, Rezaie Kahkhaie K, Afshari AR, Soukhtanloo M. Role of AKT and mTOR signaling pathways in the induction of epithelial-mesenchymal transition (EMT) process. Biochimie. 2019;165:229\u201334. https:\/\/doi.org\/10.1016\/j.biochi.2019.08.003.","journal-title":"Biochimie"},{"key":"690_CR54","doi-asserted-by":"publisher","first-page":"1230681","DOI":"10.3389\/fimmu.2023.1230681","volume":"14","author":"J Gu","year":"2023","unstructured":"Gu J, Lv X, Li W, Li G, He X, Zhang Y, et al. Deciphering the mechanism of Peptostreptococcus anaerobius-induced chemoresistance in colorectal cancer: the important roles of MDSC recruitment and EMT activation. Front Immunol. 2023;14:1230681. https:\/\/doi.org\/10.3389\/fimmu.2023.1230681.","journal-title":"Front Immunol"},{"key":"690_CR55","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.3389\/fphar.2020.01250","volume":"11","author":"J Zhang","year":"2020","unstructured":"Zhang J, Miller Z, Musich PR, Thomas AE, Yao ZQ, Xie Q, et al. DSTYK Promotes Metastasis and Chemoresistance via EMT in Colorectal Cancer. Front Pharmacol. 2020;11:1250. https:\/\/doi.org\/10.3389\/fphar.2020.01250.","journal-title":"Front Pharmacol"},{"key":"690_CR56","doi-asserted-by":"publisher","DOI":"10.2174\/0118715206365310250310081445","author":"S Mehrabadi","year":"2025","unstructured":"Mehrabadi S. Unraveling the Role of Tumor-infiltrating Immune Cells in Modulating Cancer Drug Resistance. Anti-cancer Agents Med Chem. 2025. https:\/\/doi.org\/10.2174\/0118715206365310250310081445.","journal-title":"Anti-cancer Agents Med Chem"},{"issue":"1","key":"690_CR57","doi-asserted-by":"publisher","first-page":"2141007","DOI":"10.1080\/2162402X.2022.2141007","volume":"11","author":"JD Weaver","year":"2022","unstructured":"Weaver JD, Stack EC, Bugge JA, Hu C, McGrath L, Mueller A, et al. Differential expression of CCR8 in tumors versus normal tissue allows specific depletion of tumor-infiltrating T regulatory cells by GS-1811, a novel Fc-optimized anti-CCR8 antibody. Oncoimmunology. 2022;11(1):2141007. https:\/\/doi.org\/10.1080\/2162402X.2022.2141007.","journal-title":"Oncoimmunology"},{"issue":"Pt A","key":"690_CR58","doi-asserted-by":"publisher","first-page":"113105","DOI":"10.1016\/j.intimp.2024.113105","volume":"142","author":"X Zheng","year":"2024","unstructured":"Zheng X, Tong T, Duan L, Ma Y, Lan Y, Shao Y, et al. VSIG4 induces the immunosuppressive microenvironment by promoting the infiltration of M2 macrophage and Tregs in clear cell renal cell carcinoma. Int Immunopharmacol. 2024;142(Pt A):113105. https:\/\/doi.org\/10.1016\/j.intimp.2024.113105.","journal-title":"Int Immunopharmacol"},{"key":"690_CR59","doi-asserted-by":"publisher","first-page":"119132","DOI":"10.1016\/j.lfs.2021.119132","volume":"284","author":"V Karpisheh","year":"2021","unstructured":"Karpisheh V, Mousavi SM, Naghavi Sheykholeslami P, Fathi M, Mohammadpour Saray M, Aghebati-Maleki L, et al. The role of regulatory T cells in the pathogenesis and treatment of prostate cancer. Life Sci. 2021;284:119132. https:\/\/doi.org\/10.1016\/j.lfs.2021.119132.","journal-title":"Life Sci"},{"issue":"1","key":"690_CR60","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1186\/s40425-019-0701-2","volume":"7","author":"D Wang","year":"2019","unstructured":"Wang D, Yang L, Yu W, Wu Q, Lian J, Li F, et al. Colorectal cancer cell-derived CCL20 recruits regulatory T cells to promote chemoresistance via FOXO1\/CEBPB\/NF-kappaB signaling. J Immunother Cancer. 2019;7(1):215. https:\/\/doi.org\/10.1186\/s40425-019-0701-2.","journal-title":"J Immunother Cancer"},{"key":"690_CR61","doi-asserted-by":"publisher","first-page":"102679","DOI":"10.1016\/j.tranon.2026.102679","volume":"65","author":"H Zhang","year":"2026","unstructured":"Zhang H, Lin H, Wang J, Wu D, Wang Q, Mei J, et al. Tumor-stroma contributes to immunotherapeutic resistance in non-small cell lung cancer via SEMA3C-mediated immunosuppressive tumor microenvironment. Translational Oncol. 2026;65:102679. https:\/\/doi.org\/10.1016\/j.tranon.2026.102679.","journal-title":"Translational Oncol"},{"key":"690_CR62","doi-asserted-by":"publisher","first-page":"1678907","DOI":"10.3389\/fimmu.2025.1678907","volume":"16","author":"Y Wang","year":"2025","unstructured":"Wang Y, Lu K, Xu Y, Xu S, Chu H, Fang X. Antibody-drug conjugates as immuno-oncology agents in colorectal cancer: targets, payloads, and therapeutic synergies. Front Immunol. 2025;16:1678907. https:\/\/doi.org\/10.3389\/fimmu.2025.1678907.","journal-title":"Front Immunol"}],"container-title":["Hereditas"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41065-026-00690-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41065-026-00690-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41065-026-00690-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T23:30:29Z","timestamp":1785454229000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s41065-026-00690-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,28]]},"references-count":62,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["690"],"URL":"https:\/\/doi.org\/10.1186\/s41065-026-00690-x","relation":{},"ISSN":["1601-5223"],"issn-type":[{"value":"1601-5223","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,28]]},"assertion":[{"value":"14 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethical approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"84"}}